Background Two strategies for prevention of upper gastrointestinal (UGI) events for nonselective nonsteroidal anti-inflammatory drug (nsNSAID) users are replacement of the nsNSAID by a cyclo-oxygenase-2-selective inhibitor (coxib) or co-prescription of a gastroprotective agent (GPA). Aim To identify whether and in whom either of these strategies should be preferred in daily practice. Methods A nested case-control study was conducted using three European primary care databases. We selected a cohort including all naive nsNSAID+GPA (80% GPA adherence) and coxib users (without GPA use) aged 50years. Cases with an UGI event (i.e. symptomatic UGI ulcer or bleeding) were matched to cohort members without an UGI event on age, sex and number of individual UGI risk factors (i.e. UGI event history, age 65years, concomitant use of anticoagulants, antiplatelets, or glucocorticoids) and calendar time. Conditional logistic regression analysis was used to calculate odds ratios (ORs) with 95% CI, while adjusting for potential confounders. Results Within the NSAID cohort (n=617220), 398 UGI cases were identified. The risk of UGI events was equivalent for coxib and nsNSAID+GPA (80% adherence) users (OR: 1.02; 95%CI: 0.77-1.37). In concurrent glucocorticoid users, the risk of UGI events was significantly elevated for nsNSAID+GPA (80% adherence) compared with coxib users (OR: 9.01; 95%CI: 1.61-50.50). Conclusions The risk of UGI events was similar in nsNSAID+GPA (80% adherence) and coxibs users. In patients concurrently using glucocorticoids, a significant increase in the risk of UGI events for nsNSAID+GPA users was observed and coxibs should be preferred.

Masclee, G., Valkhoff, V., van Soest, E., Schade, R., Mazzaglia, G., Molokhia, M., et al. (2013). Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 38(2), 178-189 [10.1111/apt.12348].

Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?

Mazzaglia, G;
2013

Abstract

Background Two strategies for prevention of upper gastrointestinal (UGI) events for nonselective nonsteroidal anti-inflammatory drug (nsNSAID) users are replacement of the nsNSAID by a cyclo-oxygenase-2-selective inhibitor (coxib) or co-prescription of a gastroprotective agent (GPA). Aim To identify whether and in whom either of these strategies should be preferred in daily practice. Methods A nested case-control study was conducted using three European primary care databases. We selected a cohort including all naive nsNSAID+GPA (80% GPA adherence) and coxib users (without GPA use) aged 50years. Cases with an UGI event (i.e. symptomatic UGI ulcer or bleeding) were matched to cohort members without an UGI event on age, sex and number of individual UGI risk factors (i.e. UGI event history, age 65years, concomitant use of anticoagulants, antiplatelets, or glucocorticoids) and calendar time. Conditional logistic regression analysis was used to calculate odds ratios (ORs) with 95% CI, while adjusting for potential confounders. Results Within the NSAID cohort (n=617220), 398 UGI cases were identified. The risk of UGI events was equivalent for coxib and nsNSAID+GPA (80% adherence) users (OR: 1.02; 95%CI: 0.77-1.37). In concurrent glucocorticoid users, the risk of UGI events was significantly elevated for nsNSAID+GPA (80% adherence) compared with coxib users (OR: 9.01; 95%CI: 1.61-50.50). Conclusions The risk of UGI events was similar in nsNSAID+GPA (80% adherence) and coxibs users. In patients concurrently using glucocorticoids, a significant increase in the risk of UGI events for nsNSAID+GPA users was observed and coxibs should be preferred.
Articolo in rivista - Articolo scientifico
NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; ULCER COMPLICATIONS; RHEUMATOID-ARTHRITIS; SMALL-BOWEL; BACTERIAL OVERGROWTH; CHRONIC USERS; CELECOXIB; RISK
English
2013
38
2
178
189
reserved
Masclee, G., Valkhoff, V., van Soest, E., Schade, R., Mazzaglia, G., Molokhia, M., et al. (2013). Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 38(2), 178-189 [10.1111/apt.12348].
File in questo prodotto:
File Dimensione Formato  
2013 Alimentary Pharmacol Ther.pdf

Solo gestori archivio

Dimensione 185.48 kB
Formato Adobe PDF
185.48 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/223282
Citazioni
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
Social impact